Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls

Journal of Alzheimer's Disease

Volumn 22, Issue 4, 2010, Pages 1223-1230

  Sundelöf, Johan ^a   Sundström, Johan ^a   Hansson, Oskar ^b,c   Eriksdotter Jönhagen, Maria ^d   Giedraitis, Vilmantas ^a   Larsson, Anders ^a   Degerman Gunnarsson, Malin ^a   Ingelsson, Martin ^a   Minthon, Lennart ^b,c   Blennow, Kaj ^e   Kilander, Lena ^a   Basun, Hans ^a   Lannfelt, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; biomarkers; case control study; cathepsin B; cystatin C; epidemiology; risk factor

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CATHEPSIN B; CYSTATIN C; TAU PROTEIN;

AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; TURBIDIMETRY;

EID: 79751521177     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101023     Document Type: Article

References (28)

1. Wimo A, Jonsson L, Winblad B (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21, 175-181. (Pubitemid 43201328)
2. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-31.
3. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3, 75-80.
4. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124.
5. Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248, 492-495.
6. Rawlings ND, Morton FR, Barrett AJ (2006) MEROPS: the peptidase database. Nucleic Acids Res 34, D270-272.
7. Mort JS, Buttle DJ (1997) Cathepsin B. Int J Biochem Cell Biol 29, 715-720. (Pubitemid 27323159)
8. Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6, 764-775. (Pubitemid 44450465)
9. Deng A, Irizarry MC, Nitsch RM, Growdon JH, Rebeck GW (2001) Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol 159, 1061-1068. (Pubitemid 32847196)
10. Cataldo AM, Thayer CY, Bird ED, Wheelock TR, Nixon RA (1990) Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. Brain Res 513, 181-192. (Pubitemid 20132254)
11. Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F (2001) Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neu-ropathol Exp Neurol 60, 94-104. (Pubitemid 32097009)
12. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, Lane W, Hook G, Reisine T (2005) Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol Chem 386, 931-940. (Pubitemid 41448149)
13. Klein DM, Felsenstein KM, Brenneman DE (2009) Cathep-sins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther 328, 813-821.
14. Hook VY, Kindy M, Reinheckel T, Peters C, Hook G (2009) Genetic cathepsin B deficiency reduces beta-amyloid in trans-genic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun 386, 284-288.
15. Hook VY, Kindy M, Hook G (2008) Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem 283, 7745-7753.
16. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L (2006) Antiamyloidogenic and neuroprotective functions ofcathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714. (Pubitemid 44374903)
17. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L (2008) Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60, 247-257.
18. De Strooper B Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90, 465-494.
19. Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingels-son M, Minthon L, Blennow K, Kilander L, Basun H, Lan-nfelt L Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 21, 471-478.
20. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Van-mechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
21. Vanmechelen E, Vanderstichele H, Davidsson P, Van Ker-schaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52. (Pubitemid 30224621)
22. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
23. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
24. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wis-niewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105. (Pubitemid 30027637)
25. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, En-gelborghs S (2009) No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 55, 820-825.
26. Lee JM, Markus HS (2006) Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy? Neurology 66, 6-7. (Pubitemid 43739581)
27. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E (2004) Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25, 1033-1043. (Pubitemid 38798065)
28. Nagai A, Murakawa Y, Terashima M, Shimode K, Umegae N, Takeuchi H, Kobayashi S (2000) Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 55, 1828-1832. (Pubitemid 32103964)